Triasima Portfolio Management inc. Acquires 806 Shares of Stryker Corporation (NYSE:SYK)

Triasima Portfolio Management inc. boosted its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 25.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,996 shares of the medical technology company's stock after acquiring an additional 806 shares during the quarter. Triasima Portfolio Management inc.'s holdings in Stryker were worth $1,488,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its stake in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after acquiring an additional 609 shares in the last quarter. Proficio Capital Partners LLC raised its stake in shares of Stryker by 46.2% in the 4th quarter. Proficio Capital Partners LLC now owns 1,656 shares of the medical technology company's stock valued at $596,000 after acquiring an additional 523 shares in the last quarter. GWN Securities Inc. bought a new position in shares of Stryker in the 4th quarter valued at approximately $231,000. Creative Financial Designs Inc. ADV raised its stake in shares of Stryker by 25.6% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 398 shares of the medical technology company's stock valued at $143,000 after acquiring an additional 81 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in shares of Stryker by 1.9% in the 4th quarter. Parallel Advisors LLC now owns 15,712 shares of the medical technology company's stock valued at $5,657,000 after acquiring an additional 300 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director directly owned 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 5.90% of the company's stock.

Stryker Price Performance

Stryker stock traded down $1.85 on Thursday, reaching $389.02. The company's stock had a trading volume of 1,039,118 shares, compared to its average volume of 1,352,169. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. The company has a market cap of $148.49 billion, a price-to-earnings ratio of 52.57, a PEG ratio of 2.95 and a beta of 0.91. The business's fifty day moving average price is $385.38 and its 200 day moving average price is $377.55. Stryker Corporation has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The business's revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.50 earnings per share. Equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker's dividend payout ratio is presently 45.41%.

Wall Street Analyst Weigh In

SYK has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. Citigroup reaffirmed a "buy" rating and issued a $455.00 price target (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Truist Financial lifted their price target on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research report on Monday, May 5th. Finally, Evercore ISI lifted their price target on Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $428.55.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.